The Battle for the Future of American Healthcare
October 26, 2020
Did the forecasted drug pricing storm come to pass following the 2016 US election? And what might the 2020 elections mean for pharma and the Affordable Healthcare Act?
0 min read
October 2020
In this month’s issue of The Medicine Maker, we sit down with Richard M. Johnson, President, and Chief Executive Officer of the Parenteral Drug Association, who shares some career-defining experiences with us. In Business, we examine the state of US pharma and what the upcoming election could mean for the industry. Kiran Mazumdar-Shaw also shares the story behind Biocon’s biopharmaceutical success. In NextGen, we ask Duncan Peyton, Chief Executive Officer at 4D pharma about the importance of live biotherapeutics, and in our cover feature, we explore the challenges and opportunities that await African pharma.
Harnessing Dark Data
October 24, 2020
The pharma industry creates significant amounts of data – so why is most of it hoarded and never made accessible?
0 min read
Business & Regulation
Business & Trends
Regulation & Standards
Facilities & Equipment
Technology & Manufacturing
Crisis Point
October 23, 2020
How are African countries handling the COVID-19 outbreak?
0 min read
Stemming the Brain Drain
October 22, 2020
Can African professionals be persuaded to pursue opportunities at home?
0 min read
Business & Regulation
Business & Trends
Regulation & Standards
Facilities & Equipment
Technology & Manufacturing
Why the African Medicines Agency’s Hour Has Arrived
October 21, 2020
Can the African Medicines Agency mobilize quickly enough to respond to growing healthcare issues?
0 min read
Serving a Rising Power
October 21, 2020
The gene and cell therapy market is growing, but does it have the CDMO support needed to maintain its upward trajectory?
0 min read
A Living Elixir?
October 19, 2020
Live biotherapeutics are microorganisms isolated from the human gut with the potential to treat diseases such as Crohn’s, cancer and even Alzheimer’s. Duncan Peyton, Chief Executive Officer at 4D pharma, walks us through its pipeline, including oncology, and why the inherent safety profile of this new class of medicines makes them so exciting for developers – and patients.
0 min read
Don’t Exclude the Aged
October 14, 2020
Most clinical trials against COVID-19 exclude the very patients most at risk from the disease
0 min read
Top Tier Innovation
October 13, 2020
Nominate the top pharmaceutical technologies in our 2020 Innovation Awards
0 min read
A Wealth of Experience
October 6, 2020
Sitting Down With… Richard M. Johnson, President, and Chief Executive Officer, Parenteral Drug Association
0 min read
Focus on Quality – and the Rest Will Follow
September 29, 2020
Amgen developed the Multi-Attribute Method (MAM) to obtain high-fidelity understanding of the quality of its own biologics – which is raising the bar across the biopharmaceutical industry
0 min read
Animal Alternatives
September 14, 2020
Developing in vitro methods that help vaccine developers reduce animal testing
1 min read
Zero Defects
August 10, 2020
Lives and livelihoods depend on accelerating large molecule drug production, so biopharma companies must minimize defects and contamination
0 min read
A Model Experiment
August 5, 2020
Harnessing the potential of microphysiological systems to advance drug discovery
0 min read
